Resch Ulrike, Tatzber Franz, Budinsky Alexandra, Sinzinger Helmut
Medical University of Vienna, Wilhelm Auerswald Atherosclerosis Research Group, Vienna, Austria.
Br J Clin Pharmacol. 2006 Mar;61(3):262-74. doi: 10.1111/j.1365-2125.2005.02568.x.
To examine the effect of 24 weeks' rosuvastatin treatment on oxidative stress and changes in immune response to oxidized low-density lipoprotein (LDL).
This was an open-label study of patients in Austria receiving 10 or 40 mg rosuvastatin daily alternately during 12 and 24 weeks. Circulating concentrations of antibodies to malondialdehyde-oxidized LDL (MDA-LDL), both IgG and IgM type, to copper-oxidized LDL (Cu-OxLDL-IgG), concentrations of oxidized LDL complexed to IgG (OxLDL-IC) and markers of oxidative stress and systemic inflammation in subjects with plasma LDL cholesterol concentrations between 130 mg dl-1 and 250 mg dl-1 and triglycerides<or=400 mg dl-1 were determined.
During statin therapy, plasma endogenous peroxides (POX-ACT) concentrations and peroxidase activity were significantly decreased, associated with a modest increase in total antioxidant capacity (TAC). Antibody titres to MDA-LDL-IgM, Cu-OxLDL-IgG and OxLDL-IC decreased, whereas MDA-LDL-IgG concentrations were increased after therapy. These changes were dose- and LDL-independent. POX-ACT concentrations were significantly positively correlated with inflammation markers before and after therapy and inversely with high-density lipoprotein-cholesterol concentrations after therapy.
This study provides in vivo evidence that rosuvastatin significantly reduces oxidative stress and has immunomodulatory properties in a dose- and LDL-independent manner.
研究瑞舒伐他汀24周治疗对氧化应激及氧化型低密度脂蛋白（LDL）免疫反应变化的影响。
这是一项开放标签研究，奥地利的患者在12周和24周期间每日交替服用10毫克或40毫克瑞舒伐他汀。测定血浆LDL胆固醇浓度在130毫克/分升至250毫克/分升之间且甘油三酯≤400毫克/分升的受试者中，丙二醛氧化LDL（MDA-LDL）的IgG和IgM型抗体、铜氧化LDL（Cu-OxLDL-IgG）的循环浓度、与IgG结合的氧化LDL复合物（OxLDL-IC）的浓度以及氧化应激和全身炎症标志物。
在他汀类药物治疗期间，血浆内源性过氧化物（POX-ACT）浓度和过氧化物酶活性显著降低，同时总抗氧化能力（TAC）适度增加。MDA-LDL-IgM、Cu-OxLDL-IgG和OxLDL-IC的抗体滴度降低，而治疗后MDA-LDL-IgG浓度升高。这些变化与剂量和LDL无关。治疗前后POX-ACT浓度与炎症标志物显著正相关，与治疗后高密度脂蛋白胆固醇浓度呈负相关。
本研究提供了体内证据，表明瑞舒伐他汀以剂量和LDL无关的方式显著降低氧化应激并具有免疫调节特性。
